AbbVie stunned investors with stronger-than-expected quarterly results, driven by explosive growth in its immunology drugs Skyrizi and Rinvoq, which more than offset the steep decline in Humira sales. Skyrizi revenue surged 62% to $4.42 billion, while Rinvoq jumped 42% to $2.03 billion—both surpassing analyst forecasts. Humira, once the company’s top seller, plummeted 58% to $1.18 billion due to biosimilar competition. The neurology division also impressed, with a 24% revenue increase to $2.68 billion, fueled by migraine treatments Ubrelvy and Qulipta. AbbVie raised its full-year adjusted earnings forecast to $11.88–$12.08 per share, up from $11.67–$11.87, after reporting Q2 earnings of $2.97 per share, beating estimates.
Momentum Builds Post-Humira Era
The pharmaceutical giant’s stock soared nearly 6% to $199.70, reflecting renewed confidence in its ability to replace lost Humira revenue. Quarterly sales climbed 6.6% to $15.42 billion, exceeding Wall Street expectations. Analysts highlight AbbVie’s strategic acquisitions, including potential billion-dollar deals in psychiatry, as key to sustaining growth. With robust pipeline performance and upwardly revised guidance, the company appears to have successfully navigated its post-Humira transition, signaling a potential long-term recovery.
